Search results for Precision Medicine

Operationalizing Precision Medicine 2026: U.S. Health Systems Scale Genetic Testing and AI Integration 

What You Should Know Precision medicine has transitioned from “one-off” testing to organized institutional programs at more than three-quarters of surveyed U.S. health systems, acc...

Precision Medicine’s Next Hurdle Isn’t Science — It’s Execution

A new UPMC report found that while most health systems now offer precision medicine programs, many still face challenges scaling them due to reimbursement, data integration and pat...

Personalised Medicine is the Buzz Word…but where is it in MS?

Personalized medicine has been a mantra for some years but in many cases this is just a pipedream. Personalization means screening to do selection and this equates to cost. It also...

Glasgow stroke victim gets personalised medication to fit his DNA

Matthew McKinnon, 88, agreed to take part in trial running in Glasgow, and he's one of 2,000 using medication tailored to his genetic make-up.

The Largest Metabolomics Study Ever Just Pointed To A New Future In Medicine

Welcome to the future of personalized medicine

From Trial-and-Error to Data-Driven Oncology Decision Making: AI-Enabled Functional Precision Medicine Is Rewriting the...

When cancer treatment fails, physicians face one of the hardest questions in medicine: what should come next? Having recently cared for a young patient whose cancer had returned de...

Life Science Update | March 2026

Advances in AI and genomic analysis will allow medical providers to tailor treatment for individual patients at the genome level, but challenges exist for protecting AI-assisted in...

<![CDATA[Bridging the Precision Gap: Accelerating Clinical Adoption of Companion Diagnostics in Oncology]]>

Breast cancer’s next precision medicine revolution may lie in molecular residual disease

New data shows potential for ctDNA to guide treatment decisions for patients with triple-negative breast cancer

MJFF renames study Parkinson’s Precision Medicine Initiative

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) changed the name of its large, observational study of Parkinson’s disease patients from the Parkinson’s Progression Ma...

MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration

As MRD shifts from prognostic marker to intervention trigger, sponsors must rethink trial design, endpoints and decision-making.

Precision psychiatry is finally catching up to medicine

One of the hardest parts of practicing psychiatry is that we still cannot reliably predict which medication will work for which patient. A patient comes in struggling with depressi...

Precision psychiatry is finally catching up to medicine

One of the hardest parts of practicing psychiatry is that we still cannot reliably predict which medication will work for which patient. A patient comes in struggling with depressi...

Precision psychiatry is finally catching up to medicine

One of the hardest parts of practicing psychiatry is that we still cannot reliably predict which medication will work for which patient. A patient comes in struggling with depressi...

Personalized Metabolite Biomarkers Uncover Parkinson’s Diversity

In a groundbreaking development that promises to reshape our understanding of Parkinson’s disease, researchers E. Abdik and T. Çakır have unveiled a pioneering approach employing p...

It’s time to take genetic testing off the pedestal 

For years, genetic testing has been treated as something rare and exceptional—a highly specialized tool ordered only by geneticists and often reserved for the end of a long diagnos...

What is your AI drug repurposing strategy missing?

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Biomarkers are reshaping oncology trial design

Discover how biomarker strategies are transforming oncology trials and accelerating precision medicine breakthroughs.

Finding the Right Five Percent: How Machine Learning Is Reshaping Care Management

Population Health Has a Precision Problem Population health programs continue to rely on blunt tools. Many risk stratification approaches emphasize historical utilization—basic ris...

AI Drug Discovery Is Reshaping Longevity Medicine. Is Your Practice Ready?

More therapeutic options times more data per option times the same number of clinical hours equals something that breaks. The practices that will thrive when the next wave of longe...

Gene Editing at Scale, Clinic Seeks Generalizable Therapies

What’s most exciting about CRISPR is its potential to shift medicine from managing disease to directly correcting its root cause. End-to-end pipelines and regulatory advances aim t...

Medgenome unveils india’s first study demonstrating the clinical impact of RNA-based NGS in sarcoma diagnosis

RNA sequencing improves sarcoma diagnosis by detecting gene fusions and refining classifications, enabling more accurate treatment decisions and better patient...

How MRD Testing Is Reshaping Breast Cancer Risk Assessment

New B-59 data shows circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing can better predict recurrence risk and help guide more personalized care in TNBC.

The Intelligence Gap: Why Oncologists Are Buried in Data While Patients Wait for Breakthroughs

In 2026, we live in an era of seamless predictive intelligence. For example: My shopping app often anticipates what I’ll need before I’ve even thought about it. My navigation app q...